Progress and controversy surrounding vaccines against Lyme disease

Expert Review of Vaccines

Volumn 2, Issue 5, 2003, Pages 683-703

  Hanson, Mark S ^b,c   Edelman, Robert ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b MEDIMMUNE   (United States)

^c LTS Corporation   (United States)

Author keywords

Borrelia burgdorferi; Borrelia immunity; Canine Lyme disease vaccine; Human Lyme disease vaccine; Ixodes ticks; Lyme disease; Lyme disease serology; Phase I, II, III clinical trials; Rick borne infections

Indexed keywords

'GALAXY'; BB VACCINE; BCG VACCINE; DBPA VACCINE; LYME DISEASE VACCINE; LYMEVAX; MEMBRANE PROTEIN; OUTER SURFACE PROTEIN A VACCINE; OUTER SURFACE PROTEIN B VACCINE; OUTER SURFACE PROTEIN C VACCINE; RECOMBINANT BCG OSPA VACCINE; RECOMBITEK; UNCLASSIFIED DRUG;

ANTIGENIC MODULATION; ARTHRALGIA; ARTHRITIS; ATRIOVENTRICULAR BLOCK; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; BORRELIA BURGDORFERI; CHILL; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG MANUFACTURE; DRUG MARKETING; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; FATIGUE; FEVER; FLU LIKE SYNDROME; GENOMICS; HEADACHE; HUMAN; HYPERSENSITIVITY REACTION; INFECTIOUS ARTHRITIS; INFLAMMATION; LYME DISEASE; MUSCULOSKELETAL DISEASE; MYALGIA; NONHUMAN; PAIN; POLYARTHRITIS; PRIORITY JOURNAL; REVIEW; TENOSYNOVITIS; VACCINATION;

ANIMALS; BORRELIA BURGDORFERI GROUP; DOG DISEASES; DOGS; HUMANS; LYME DISEASE; LYME DISEASE VACCINES;

EID: 0142249315     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.2.5.683     Document Type: Review

References (214)

1. Steere AC. LD. N. Engl. J. Med. 345, 115-125 (2001). An excellent, authoritative general review of LD
2. Burgdorfer W, Barbour AG, Hayes SF, Benach JL, Grunwaldt E, Davis JP. LD-a tick-borne spirochetosis? Science 216, 1317-1319 (1982).
3. Benach JL, Bosler EM, Hanrahan JP et al. Spirochetes isolated from the blood of two patients with LD. N. Engl. J. Med. 308, 740-742 (1983).
4. Wang G, van Dam AP, Schwartz I, Dankert J. Molecular typing of Borrelia burgdorferi sensu lato: taxonomic, epidemiological and clinical implications. Clin. Microbiol. Rev. 12, 633-653 (1999).
5. van Dam AP, Kuiper H, Vos K et al. Different genospecies of Borrelia burgdorferi are associated with distinct clinical manifestations of Lyme borreliosis. Clin. Infect. Dis. 17, 708-717 (1993).
6. Strle F. Lyme borreliosis in Slovenia. Zentralbl. Bakteriol. 289, 643-652 (1999).
7. James AM, Liveris D, Wormser GP, Schwartz I, Montecalvo MA, Johnson BJ. Borrelia lonestari infection after a bite by an Amblyomma americanum tick. J. Infect. Dis. 183, 1810-1814 (2001).
8. Anderson JF, Magnarelli LA. A tick-associated disease originally described in Europe but named after a town in Connecticut. Am. Entomol. 217-227 (1994).
9. Steere AC, Malawista SE, Snydman DR et al. Lyme arthritis: an epidemic of oligoarticular arthritis in children and adults in three Connecticut communities. Arthritis Rheum. 20, 7-17 (1977).
10. Scrimenti RJ. Erythema chronicum migrans. Arch. Dermatol. 102, 104-105 (1970).
11. Schmid GP. The global distribution of LD. Rev. Infect. Dis. 7, 41-50 (1985).
12. Summary of Notifiable Diseases - United States, 2001. Morbid. Mortal. Wkly Rep. 50(53), 1-108 (2003).
13. Coyle BS, Strickland GT, Liang YY, Pena C, McCarter R, Israel E. The public health impact of LD in Maryland. J. Infect. Dis. 173, 1260-1262 (1996).
14. Fish D. Environmental risk and prevention of LD. Am. J. Med. 98, 2S-8S (1995).
15. Klempner MS, Noring R, Rogers RA. Invasion of human skin fibroblasts by the LD spirochete, Borrelia burgdorferi. J. Infect. Dis. 167, 1074-1081 (1993).
16. Dattwyler RJ, Halperin JJ, Volkman DJ, Luft BJ. Treatment of late Lyme borreliosis - randomised comparison of ceftriaxone and penicillin. Lancet 1, 1191-1194 (1988).
17. Duray PH, Johnson RC. The histopathology of experimentally infected hamsters with the LD spirochete, Borrelia burgdorferi. Proc. Soc. Exp. Biol. Med. 181, 263-269 (1986).
18. Hejka A, Schmitz JL, England DM, Callister SM, Schell RF. Histopathology of Lyme arthritis in LSH hamsters. Am. J. Pathol. 134, 1113-1123 (1989).
19. Shadick NA, Phillips CB, Logigian EL et al. The long-term clinical outcomes of LD. A population-based retrospective cohort study. Ann. Intern. Med. 121, 560-567 (1994).
20. Klempner MS, Hu LT, Evans J et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of LD. N. Engl. J. Med. 345, 85-92 (2001).
21. Steere AC, Dwyer E, Winchester R. Association of chronic Lyme arthritis with HLA-DR4 and HLA-DR2 alleles. N. Engl. J. Med. 323, 219-223 (1990). Erratum appears in N. Engl. J. Med. 324(2), 129 (1991).
22. Steere AC, Dwyer E, Winchester R. Association of chronic Lyme arthritis with HLA-DR4 and HLA-DR2 alleles. N. Engl. J. Med. 323, 219-223 (1990). Erratum appears in N. Engl. J. Med. 324(2), 129 (1991).
23. Kalish RA, Leong JM, Steere AC. Association of treatment-resistant chronic Lyme arthritis with HLA-DR4 and antibody reactivity to OspA and OspB of Borrelia burgdorferi. Infect. Immun. 61, 2774-2779 (1993).
24. Kalish RA, Leong JM, Steere AC. Early and late antibody responses to full-length and truncated constructs of outer surface protein A of Borrelia burgdorferi in LD. Infect. Immun. 63, 2228-2235 (1995).
25. Dressler F, Whalen JA, Reinhardt BN, Steere AC. Western blotting in the serodiagnosis of LD. J. Infect. Dis. 167, 392-400 (1993).
26. Aguero-Rosenfeld ME, Nowakowski J, McKenna DF, Carbonaro CA, Wormser GP. Serodiagnosis in early LD. J. Clin. Microbiol. 31, 3090-3095 (1993).
27. Fung BP, McHugh GL, Leong JM, Steere AC. Humoral immune response to outer surface protein C of Borrelia burgdorferi in LD: role of the immunoglobulin M response in the serodiagnosis of early infection. Infect. Immun. 62, 3213-3221 (1994).
28. Craft JE, Fischer DK, Shimamoto GT, Steere AC. Antigens of Borrelia burgdorferi recognized during LD. Appearance of a new immunoglobulin M response and expansion of the immunoglobulin G response late in the illness. J. Clin. Invest. 78, 934-939 (1986).
29. Fikrig E, Huguenel ED, Berland R, Rahn DW, Hardin JA, Flavell RA. Serologic diagnosis of LD using recombinant outer surface proteins A and B and flagellin. J. Infect. Dis. 165, 1127-1132 (1992).
30. Kalish RA, McHugh G, Granquist J, Shea B, Ruthazer R, Steere AC. Persistence of immunoglobulin M or immunoglobulin G antibody responses to Borrelia burgdorferi 10-20 years after active LD. Clin. Infect. Dis. 33, 780-785 (2001).
31. Barbour AG, Tessier SL, Todd WJ. LD spirochetes and ixodid tick spirochetes share a common surface antigenic determinant defined by a monoclonal antibody. Infect. Immun. 41, 795-804 (1983).
32. Will G, Jauris-Heipke S, Schwab E et al. Sequence analysis of OspA genes shows homogeneity within Borrelia burgdorferi sensu stricto and Borrelia afzelii strains but reveals major subgroups within the Borrelia garinii species. Med. Microbiol. Immunol. (Berl) 184, 73-80 (1995).
33. Wilske B, Preac-Mursic V, Gobel UB et al. An OspA serotyping system for Borrelia burgdorferi based on reactivity with monoclonal antibodies and OspA sequence analysis. J. Clin. Microbiol. 31, 340-350 (1993).
34. Sadziene A, Jonsson M, Bergstrom S, Bright RK, Kennedy RC, Barbour AG. A bactericidal antibody to Borrelia burgdorferi is directed against a variable region of the OspB protein. Infect. Immun. 62, 2037-2045 (1994).
35. Shoberg RJ, Jonsson M, Sadziene A, Bergstrom S, Thomas DD. Identification of a highly cross-reactive outer surface protein B epitope among diverse geographic isolates of Borrelia spp. causing LD. J. Clin. Microbiol. 32, 489-500 (1994).
36. Jauris-Heipke S, Liegl G, Preac-Mursic V et al. Molecular analysis of genes encoding outer surface protein C (OspC) of Borrelia burgdorferi sensu lato: relationship to OspA genotype and evidence of lateral gene exchange of OspC. J. Clin. Microbiol. 33, 1860-1866 (1995).
37. Wilske B, Jauris-Heipke S, Lobentanzer R et al. Phenotypic analysis of outer surface protein C (OspC) of Borrelia burgdorferi sensu lato by monoclonal antibodies: relationship to genospecies and OspA serotype. J. Clin. Microbiol. 33, 103-109 (1995).
38. Pal U, Montgomery RR, Lusitani D, Voet P et al. Inhibition of Borrelia burgdorferi-tick interactions in vivo by outer surface protein A antibody. J. Immunol. 166, 7398-7403 (2001).
39. Steere AC, Grodzicki RL, Kornblatt AN et al. The spirochetal etiology of LD. N. Engl. J. Med. 308, 733-740 (1983).
40. Shadick NA, Phillips CB, Sangha O et al. Musculoskeletal and neurologic outcomes in patients with previously treated LD. Ann. Intern. Med. 131, 919-926 (1999).
41. Kalish RA, Kaplan RF, Taylor E, Jones-Woodward L, Workman K, Steere AC. Evaluation of study patients with LD, 10-20-year follow-up. J. Infect. Dis. 183, 453-460 (2001).
42. Hanrahan JP, Benach JL, Coleman JL et al. Incidence and cumulative frequency of endemic LD in a community. J. Infect. Dis. 150, 489-496 (1984).
43. Steere AC, Taylor E, Wilson ML, Levine JF, Spielman A. Longitudinal assessment of the clinical and epidemiological features of LD in a defined population. J. Infect. Dis. 154, 295-300 (1986).
44. Guy EC, Bateman DE, Martyn CN, Heckels JE, Lawton NF. LD: prevalence and clinical importance of Borrelia burgdorferi specific IgG in forestry workers. Lancet 1, 484-486 (1989).
45. Gustafson R, Svenungsson B, Gardulf A, Stiernstedt G, Forsgren M. Prevalence of tick-borne encephalitis and Lyme borreliosis in a defined Swedish population. Scand. J. Infect. Dis. 22, 297-306 (1990).
46. Fahrer H, van der Linden SM, Sauvain MJ, Gem L, Zhioua E, Aeschlimann A. The prevalence and incidence of clinical and asymptomatic Lyme borreliosis in a population at risk. J. Infect. Dis. 163, 305-310 (1991).
47. Feder HM, Jr., Gerber MA, Cartter ML, Sikand V, Krause PJ. Prospective assessment of LD in a school-aged population in Connecticut. J. Infect. Dis. 171, 1371-1374 (1995).
48. Curran KL, Fish D, Piesman J. Reduction of nymphal Ixodes dammini (Acari: Ixodidae) in a residential suburban landscape by area application of insecticides. J. Med. Entomol. 30, 107-113 (1993).
49. Deblinger RD, Wilson ML, Rimmer DW, Spielman A. Reduced abundance of immature Ixodes dammini (Acari: Ixodidae) following incremental removal of deer. J. Med. Entomol. 30, 144-150 (1993).
50. Shadick NA, Daltroy LH, Phillips CB, Liang US, Liang MH. Determinants of tick-avoidance behaviors in an endemic area for LD. Am. J. Prev. Med. 13, 265-270 (1997).
51. Anonymous. LD - United States, 1994. JAMA 274, 111 (1995).
52. Barbour AG, Fish D. The biological and social phenomenon of LD. Science 260, 1610-1616 (1993).
53. Dattwyler RJ, Volkman DJ, Luft BJ, Halperin JJ, Thomas J, Golightly MG, Seronegative LD. Dissociation of specific T- and B-lymphocyte responses to Borrelia burgdorferi. N. Engl. J. Med. 319, 1441-1446 (1988).
54. Preac-Mursic V, Weber K, Pfister HW et al. Survival of Borrelia burgdorferi in antibiotically treated patients with Lyme borreliosis. Infection 17, 355-359 (1989).
55. Johnson RC, Kodner C, Russell M. Passive immunization of hamsters against experimental infection with the LD spirochete. Infect. Immun. 53, 713-714 (1986).
56. Schmitz JL, Schell RF, Hejka A, England DM, Konick L. Induction of Lyme arthritis in LSH hamsters. Infect. Immun. 56, 2336-2342 (1988).
57. Schaible UE, Kramer MD, Museteanu C, Zimmer G, Mossmann H, Simon MM. The severe combined immunodeficiency (scid) mouse. A laboratory model for the analysis of Lyme arthritis and carditis. J. Exp. Med. 170, 1427-1432 (1989).
58. Fikrig E, Barthold SW, Kantor FS, Flavell RA. Protection of mice against the LD agent by immunizing with recombinant OspA. Science 250, 553-556 (1990).
59. Simon MM, Schaible UE, Kramer MD et al. Recombinant outer surface protein a from Borrelia burgdorferi induces antibodies protective against spirochetal infection in mice. J. Infect. Dis. 164, 123-132 (1991).
60. Preac-Mursic V, Wilske B, Patsouris E et al. Active immunization with pC protein of Borrelia burgdorferi protects gerbils against B. burgdorferi infection. Infection 20, 342-349 (1992).
61. Philipp MT, Aydintug MK, Bohm RP Jr et al. Early and early disseminated phases of LD in the rhesus monkey: a model for infection in humans. Infect. Immun. 61, 3047-3059 (1993).
62. Appel MJ, Allan S, Jacobson RH et al. Experimental LD in dogs produces arthritis and persistent infection. J. Infect. Dis. 167, 651-664 (1993).
63. Schwan TG, Piesman J, Golde WT, Dolan MC, Rosa PA. Induction of an outer surface protein on Borrelia burgdorferi during tick feeding. Proc. Natl Acad. Sci. USA 92, 2909-2913 (1995). Good study of Bb antigenic modulation during tick feeding.
64. Schwan TG, Piesman J. Temporal changes in outer surface proteins A and C of the LD-associated spirochete, Borrelia burgdorferi, during the chain of infection in ticks and mice. J. Clin. Microbiol. 38, 382-388 (2000).
65. Edelman R. Perspective on the development of vaccines against LD. Vaccine 9, 531-532 (1991).
66. Weber K, Schierz G, Wilske B et al. Reinfection in erythema migrans disease. Infection 14, 32-35 (1986).
67. Pfister HW, Neubert U, Wilske B, Preac-Mursic V, Einhaupl KM, Borasio GD. Reinfection with Borrelia burgdorferi. Lancet 2, 984-985 (1986).
68. Nowakowski J, Schwartz I, Nadelman RB, Liveris D, Aguero-Rosenfeld M, Wormser GP. Culture-confirmed infection and reinfection with Borrelia burgdorferi. Ann. Intern. Med. 127, 130-132 (1997).
69. Johnson RC, Kodner C, Russell M. Active immunization of hamsters against experimental infection with Borrelia burgdorferi. Infect. Immun. 54, 897-898 (1986).
70. Schmitz JL, Schell RF, Hejka AG, England DM. Passive immunization prevents induction of Lyme arthritis in LSH hamsters. Infect. Immun. 58, 144-148 (1990) Erratum appears in Infect. Immun. 61(2), 791 (1993).
71. Schmitz JL, Schell RF, Hejka AG, England DM. Passive immunization prevents induction of Lyme arthritis in LSH hamsters. Infect. Immun. 58, 144-148 (1990) Erratum appears in Infect. Immun. 61(2), 791 (1993).
72. Johnson RC, Kodner C, Russell M, Duray PH. Experimental infection of the hamster with Borrelia burgdorferi. Ann. NY Acad. Sci. 539, 258-263, (1988).
73. Simon MM, Schaible UE, Wallich R, Kramer MD. A mouse model for Borrelia burgdorferi infection: approach to a vaccine against LD. Immunol. Today 12, 11-16 (1991).
74. Piesman J, Maupin GO, Campos EG, Happ CM. Duration of adult female Ixodes dammini attachment and transmission of Borrelia burgdorferi, with description of a needle aspiration isolation method. J. Infect. Dis. 163, 895-897 (1991).
75. Piesman J. Dynamics of Borrelia burgdorferi transmission by nymphal Ixodes dammini ticks. J. Infect. Dis. 167, 1082-1085 (1993).
76. des VF, Piesman J, Heffernan R, Schulze TL, Stafford KC, III, Fish D. Effect of tick removal on transmission of Borrelia burgdorferi and Ehrlichia phagocytophila by Ixodes scapularis nymphs. J. Infect. Dis. 183, 773-778 (2001).
77. Kahl O, Janetzki-Mittmann C, Gray JS, Jonas R, Stein J, de Boer R. Risk of infection with Borrelia burgdorferi sensu lato for a host in relation to the duration of nymphal Ixodes ricinus feeding and the method of tick removal. Zentralbl. Bakteriol. 287, 41-52 (1998).
78. Burkot TR, Piesman J, Wirtz RA. Quantitation of the Borrelia burgdorferi outer surface protein A in Ixodes scapularis: fluctuations during the tick life cycle, doubling times and loss while feeding. J. Infect. Dis. 170, 883-889 (1994).
79. Shih CM, Spielman A, Telford SR 3rd. Short report: mode of action of protective immunity to LD spirochetes. Am. J. Trop. Med. Hyg. 52, 72-74 (1995).
80. Fikrig E, Telford SR 3rd, Barthold SW, Kantor FS, Spielman A, Flavell RA. Elimination of Borrelia burgdorferi from vector ticks feeding on OspA-immunized mice. Proc. Natl Acad. Sci. USA 89, 5418-5421 (1992). Important study of the mechanism of immunity to tick-transmitted Bb.
81. Nguyen TP, Lam TT, Barthold SW, Telford SR 3rd, Flavell RA, Fikrig E. Partial destruction of Borrelia burgdorferi within ticks that engorged on OspE- or OspF-immunized mice. Infect. Immun. 62, 2079-2084 (1994).
82. Telford SR 3rd, Kantor FS, Lobet Y, Barthold SW, Spielman A, Flavell RA, Fikrig E. Efficacy of human LD vaccine formulations in a mouse model. J. Infect. Dis. 171, 1368-1370 (1995).
83. Fikrig E, Telford SR 3rd, Wallich R et al. Vaccination against LD caused by diverse Borrelia burgdorferi. J. Exp. Med. 181, 215-221 (1995).
84. Piesman J, Mather TN, Sinsky RJ, Spielman A. Duration of tick attachment and Borrelia burgdorferi transmission. J. Clin. Microbiol. 25, 557-558 (1987).
85. de Silva AM, Telford SR 3rd, Brunet LR, Barthold SW, Fikrig E. Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking LD vaccine. J. Exp. Med. 183, 271-275 (1996). Documentation supporting the transmission-blocking mechanism of OspA immunity.
86. Gilmore RD Jr, Piesman J. Inhibition of Borrelia burgdorferi migration from the midgut to the salivary glands following feeding by ticks on OspC-immunized mice. Infect. Immun. 68, 411-414 (2000).
87. Zhong W, Stehle T, Museteanu C et al. Therapeutic passive vaccination against chronic LD in mice. Proc. Natl Acad. Sci. USA 94, 12533-12538 (1997).
88. Piesman J, Dolan MC, Happ CM et al. Duration of immunity to reinfection with tick-transmitted Borrelia burgdorferi in naturally infected mice. Infect. Immun. 65, 4043-4047 (1997).
89. Lovrich SD, Callister SM, Lim LC, DuChateau BK, Schell RF. Seroprotective groups of Lyme Borreliosis spirochetes from North America and Europe. J. Infect. Dis. 170, 115-121 (1995).
90. Schaible UE, Wallich R, Kramer MD et al. Immune sera to individual Borrelia burgdorferi isolates or recombinant OspA thereof protect SCID mice against infection with homologous strains but only partially or not at all against those of different OspA/OspB genotype. Vaccine 11, 1049-1054 (1993).
91. Hanson MS, Cassatt DR, Guo BP et al. Active and passive immunity against Borrelia burgdorferi decorin binding protein A (DbpA) protects against infection. Infect. Immun. 66, 2143-2153 (1998).
92. Probert WS, Crawford M, Cadiz RB, LeFebvre RB. Immunization with outer surface protein (Osp) A but not OspC, provides cross-protection of mice challenged with North American isolates of Borrelia burgdorferi. J. Infect. Dis. 175, 400-405 (1997).
93. Telford SR 3rd, Fikrig E, Barthold SW, Brunet LR, Spielman A, Flavell RA. Protection against antigenically variable Borrelia burgdorferi conferred by recombinant vaccines. J. Exp. Med. 178, 755-758 (1993).
94. Golde WT, Burkot TR, Piesman J et al. The LD vaccine candidate outer surface protein A (OspA) in a formulation compatible with human use protects mice against natural tick transmission of B. burgdorferi. Vaccine 13, 435-441 (1995).
95. Barthold SW. Specificity of infection-induced immunity among Borrelia burgdorferi sensu lato species. Infect. Immun. 67, 36-42 (1999).
96. Gern L, Hu CM, Voet P, Hauser P, Lobet Y. Immunization with a polyvalent OspA vaccine protects mice against Ixodes ricinus tick bites infected by Borrelia burgdorferi ss, Borrelia garinii and Borrelia afzelii. Vaccine 15, 1551-1557 (1997).
97. Lovrich SD, Callister SM, Schmitz JL, Alder JD, Schell RF. Borreliacidal activity of sera from hamsters infected with the LD spirochete. Infect. Immun. 59, 2522-2528 (1991).
98. Sadziene A, Thompson PA, Barbour AG. In vitro inhibition of Borrelia burgdorferi growth by antibodies. J. Infect. Dis. 167, 165-172 (1993). Thorough laboratory investigation of direct killing of Bb by antibodies.
99. Coleman JL, Rogers RC, Benach JL. Selection of an escape variant of Borrelia burgdorferi by use of bactericidal monoclonal antibodies to OspB. Infect. Immun. 60, 3098-3104 (1992).
100. Schmitz JL, Lovrich SD, Callister SM, Schell RF. Depletion of complement and effects on passive transfer of resistance to infection with Borrelia burgdorferi. Infect. Immun. 59, 3815-3818 (1991).
101. Scriba M, Ebrahim JS, Schlott T, Eiffert H. The 39-kilodalton protein of Borrelia burgdorferi: a target for bactericidal human monoclonal antibodies. Infect. Immun. 61, 4523-4526 (1993).
102. Callister SM, Schell RF, Case KL, Lovrich SD, Day SP. Characterization of the borreliacidal antibody response to Borrelia burgdorferi in humans: a serodiagnostic test. J. Infect. Dis. 167, 158-164 (1993).
103. Keller D, Koster FT, Marks DH, Hosbach P, Erdile LF, Mays JP. Safety and immunogenicity of a recombinant outer surface protein A Lyme vaccine. JAMA 271, 1764-1768 (1994).
104. Padilla ML, Callister SM, Schell RF et al. Characterization of the protective borreliacidal antibody response in humans and hamsters after vaccination with a Borrelia burgdorferi outer surface protein A vaccine. J. Infect. Dis. 174, 739-746 (1996).
105. Benach JL, Fleit HB, Habicht GS, Coleman JL, Bosler EM, Lane BP. Interactions of phagocytes with the LD spirochete: role of the Fc receptor. J. Infect. Dis. 150, 497-507 (1984).
106. Modolell M, Schaible UE, Rittig M, Simon MM. Killing of Borrelia burgdorferi by macrophages is dependent on oxygen radicals and nitric oxide and can be enhanced by antibodies to outer surface proteins of the spirochete. Immunol. Lett. 40, 139-146 (1994).
107. Lengl-Janssen B, Strauss AF, Steere AC, Kamradt T. The T-helper cell response in Lyme arthritis: differential recognition of Borrelia burgdorferi outer surface protein A in patients with treatment-resistant or treatment-responsive Lyme arthritis. J. Exp. Med. 180, 2069-2078 (1994).
108. Keane-Myers A, Nickell SP. T-cell subset-dependent modulation of immunity to Borrelia burgdorferi in mice. J. Immunol. 154, 1770-1776 (1995).
109. Schaible UE, Kramer MD, Eichmann K, Modolell M, Museteanu C, Simon MM. Monoclonal antibodies specific for the outer surface protein A (OspA) of Borrelia burgdorferi prevent Lyme borreliosis in severe combined immunodeficiency (scid) mice. Proc. Natl Acad. Sci. USA 87, 3768-3772 (1990).
110. Sears JE, Fikrig E, Nakagawa TY et al. Molecular mapping of Osp-A mediated immunity against Borrelia burgdorferi, the agent of LD. J. Immunol. 147, 1995-2000 (1991).
111. Van Hoecke C, Comberbach M, De Grave D et al. Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein (OspA) lyme vaccines in healthy adults. Vaccine 14, 1620-1626 (1996).
112. Van Hoecke C, Fu D, De Grave D, Voet P, Lebacq E. Clinical and immunological assessment of a candidate LD vaccine in healthy adults: antibody persistence and effect of a booster dose at month 12. Vaccine 16, 1688-1692 (1998).
113. Probert WS, LeFebvre RB. Protection of C3H/HeN mice from challenge with Borrelia burgdorferi through active immunization with OspA, OspB, or OspC but not with OspD or the 83-kilodalton antigen. Infect. Immun. 62, 1920-1926 (1994).
114. Rousselle JC, Callister SM, Schell RF et al. Borreliacidal antibody production against outer surface protein C of Borrelia burgdorferi. J. Infect. Dis. 178, 733-741 (1998).
115. Zeidner N, Dreitz M, Belasco D, Fish D. Suppression of acute Ixodes scapularis-induced Borrelia burgdorferi infection using tumor necrosis factor-α, interleukin-2 and interferon-γ. J. Infect. Dis. 173, 187-95 (1996).
116. Barthold SW, de Souza M. Exacerbation of Lyme arthritis in beige mice. J. Infect. Dis. 172, 778-784 (1995).
117. Fikrig E, Barthold SW, Kantor FS, Flavell RA. Protection of mice from Lyme borreliosis by oral vaccination with Escherichia coli expressing OspA. J. Infect. Dis. 164, 1224-1227 (1991).
118. Fikrig E, Barthold SW, Persing DH, Sun X, Kantor FS, Flavell RA. Borrelia burgdorferi strain 25015, characterization of outer surface protein A and vaccination against infection. J. Immunol. 148, 2256-2260 (1992).
119. Fikrig E, Barthold SW, Kantor FS, Flavell RA. Long-term protection of mice from LD by vaccination with OspA. Infect. Immun. 60, 773-777 (1992).
120. Fikrig E, Barthold SW, Marcantonio N, Deponte K, Kantor FS, Flavell RA. Roles of OspA, OspB and flagellin in protective immunity to Lyme borreliosis in laboratory mice. Infect. Immun. 60, 657-661 (1992).
121. Erdile LF, Brandt MA, Warakomski DJ et al. Role of attached lipid in immunogenicity of Borrelia burgdorferi OspA. Infect. Immun. 61, 81-90 (1993).
122. Steere AC, Sikand VK, Meurice F et al. Vaccination against LD with recombinant Borrelia burgdorferi Outer-surface lipoprotein A with adjuvant. N. Engl. J. Med. 339, 209-215 (1998). Pivotal trial of human LD vaccine LYMErix.
123. Sigal LH, Zahradnik JM, Lavin P et al. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent LD. N. Engl J. Med. 339, 216-222 (1998). Pivotal trial of human LD vaccine ImuLyme
124. Lissman BA, Bosler EM, Camay H, Ormiston BG, Benach JL. Spirochete-associated arthritis (LD) in a dog. J. Am. Vet. Med. Assoc. 185, 219-220 (1984).
125. Levy SA, Magnarelli LA. Relationship between development of antibodies to Borrelia burgdorferi in dogs and the subsequent development of limb/joint borreliosis. J. Am. Vet. Med. Assoc. 200, 344-347 (1992).
126. Kazmierczak JJ, Sorhage FE. Current understanding of Borrelia burgdorferi infection, with emphasis on its prevention in dogs. J. Am. Vet. Med. Assoc. 203, 1524-1528 (1993).
127. Levy SA, Lissman BA, Ficke CM. Performance of a Borrelia burgdorferi bacterin in borreliosis-endemic areas. J. Am. Vet. Med. Assoc. 202, 1834-1838 (1993).
128. Lim LC, England DM, DuChateau BK et al. Development of destructive arthritis in vaccinated hamsters challenged with Borrelia burgdorferi. Infect. Immun. 62, 2825-2833 (1994).
129. Lim LC, England DM, DuChateau BK, Glowacki NJ, Schell RF. Borrelia burgdorferi-specific T-lymphocytes induce severe destructive Lyme arthritis. Infect. Immun. 63, 1400-1408 (1995).
130. Sigal LH, Tatum AH. LD patients' serum contains IgM antibodies to Borrelia burgdorferi that cross-react with neuronal antigens. Neurology 38, 1439-1442 (1988).
131. Aberer E, Brunner C, Suchanek G et al. Molecular mimicry and Lyme borreliosis: a shared antigenic determinant between Borrelia burgdorferi and human. Ann. Neurol. 26, 732-737 (1989).
132. Mensi N, Webb DR, Turck CW, Peltz GA. Characterization of Borrelia burgdorferi proteins reactive with antibodies in synovial fluid of a patient with Lyme arthritis. Infect. Immun. 58, 2404-2407 (1990).
133. Sigal LH. Cross-reactivity between Borrelia burgdorferi flagellin and a human axonal 64,000 molecular weight protein. J. Infect. Dis. 167, 1372-1378 (1993).
134. Ma J, Bulger PA, Dante S, Davis DR, Perilli-Palmer B, Coughlin RT. Characterization of canine humoral immune responses to outer surface protein subunit vaccines and to natural infection by LD spirochetes. J. Infect. Dis. 171, 909-915 (1995).
135. Coughlin RT, Fish D, Mather TN, Ma J, Pavia C, Bulger P. Protection of dogs from LD with a vaccine containing outer surface protein (Osp) A, OspB and the saponin adjuvant QS21. J. Infect. Dis. 171, 1049-1052 (1995).
136. Ma J, Bulger PA, Davis DR et al. Impact of the saponin adjuvant QS-21 and aluminium hydroxide on the immunogenicity of recombinant OspA and OspB of Borrelia burgdorferi. Vaccine 12, 925-932 (1994).
137. Philipp MT, Lobet Y, Bohm RP Jr et al. The outer surface protein A (OspA) vaccine against LD: efficacy in the rhesus monkey. Vaccine 15, 1872-1887 (1997).
138. Schoen RT, Reimann J, Fikrig E. Safety and immunogenicity of an outer surface protein A vaccine in subjects with previous LD. J. Infect. Dis. 172, 1324-1329 (1995).
139. Van Hoecke C, Lebacq E, Beran J, Parenti D. Alternative vaccination schedules (0, 1 and 6 months versus 0, 1 and 12 months) for a recombinant OspA LD vaccine. Clin. Infect. Dis. 28, 1260-1264 (1999).
140. Schoen RT, Sikand VK, Caldwell MC et al. Safety and immunogenicity profile of a recombinant outer-surface protein A LD vaccine: clinical trial of a 3-dose schedule at 0, 1 and 2 months. Clin. Ther. 22, 315-325 (2000).
141. Feder HM Jr, Beran J, Van Hoecke C et al. Immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against LD in children. J. Pediatr. 135, 575-579 (1999).
142. Beran J, De Clercq N, Dieussaert I, Van Hoecke C. Reactogenicity and immunogenicity of a LD vaccine in children 2-5 years old. Clin. Infect. Dis. 31, 1504-1507 (2000).
143. Sikand VK, Halsey N, Krause PJ et al. Safety and immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against LD in healthy children and adolescents: a randomized controlled trial. Pediatrics 108, 123-128 (2001).
144. Kurtenbach K, Dizij A, Voet P, Hauser P, Simon MM. Vaccination of natural reservoir hosts with recombinant lipidated OspA induces a transmission-blocking immunity against LD spirochaetes associated with high levels of LA-2 equivalent antibodies. Vaccine 15, 1670-1674 (1997).
145. Golde WT, Piesman J, Dolan MC et al. Reactivity with a specific epitope of outer surface protein A predicts protection from infection with the LD spirochete, Borrelia burgdorferi. Infect. Immun. 65, 882-889 (1997).
146. Centers for Disease Control and Prevention. Recommendations for the use of LD vaccine. Morb. Mortal. Wkly Rep. 48(RR-7), 1-25 (1999).
147. Nadelman RB, Nowakowski J, Fish D et al. Prophylaxis with single-dose doxycycline for the prevention of LD after an Ixodes scapularis tick bite. N. Engl J. Med. 345, 79-84 (2001).
148. American Academy of Pediatrics. Committee on Infectious Diseases. Prevention of LD. Pediatrics 105, 142-147 (2000).
149. Parenti DL, Gillet M, Sennewald E et al. Correlate of protection for LD (LD) using LYMErix™, recombinant, adjuvanted Borrelia burgdorferi outer surface lipoprotein A (L-OspA) vaccine. Clin. Infect. Dis. 27, 1053. 1998
150. Rahn DW. Lyme vaccine: issues and controversies. Infect. Dis. Clin. N. Am. 15, 171-187 (2001).
151. Meltzer MI, Dennis DT, Orloski KA. The cost effectiveness of vaccinating against LD. Emerg. Infect. Dis. 5, 321-328 (1999).
152. Institute of medicine. Vaccines for the 21st Century: a Tool for Decisionmaking. National Academy Press, Washington DC, USA, 1-476 (1999).
153. Shadick NA, Liang MH, Phillips CB, Fossel K, Kuntz KM. The cost-effectiveness of vaccination against LD. Arch. Intern. Med. 161, 554-561 (2001).
154. Shapiro ED, Gerber MA. LD. Clin. Infect. Dis. 31, 533-542 (2000).
155. Sigal LH. Misconceptions about LD: confusions hiding behind ill-chosen terminology. Ann. Intern. Med. 136, 413-419 (2002).
156. LD Vaccine is Taken Off Market. Washington Post A10, February 27th (2002)
157. Physicians' Desk Reference. Medical Economics Company, Montvale, NJ, USA, 1592-1596 (2002).
158. Braun MM, Ellenberg SS. Descriptive epidemiology of adverse events after immunization: reports to the Vaccine Adverse Event Reporting System (VAERS), 1991-1994. J. Pediatr. 131, 529-535 (1997).
159. Lathrop SL, Ball R, Haber P et al. Adverse event reports following vaccination for LD: December 1998 - July 2000. Vaccine 20, 1603-1608 (2002).
160. Gross DM, Forsthuber T, Tary-Lehmann M et al. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science 281, 703-706 (1998). Laboratory evidence of an autoimmune target for OspA imunity
161. Trollmo C, Meyer AL, Steere AC, Hafler DA, Huber BT. Molecular mimicry in Lyme arthritis demonstrated at the single cell level: LFA-1αL is a partial agonist for outer surface protein A- reactive T-cells. J. Immunol. 166, 5286-5291 (2001).
162. Steere AC, Falk B, Drouin EE, Baxter-Lowe LA, Hammer J, Nepom GT. Binding of outer surface protein A and human lymphocyte function-associated antigen 1 peptides to HLA-DR molecules associated with antibiotic treatment-resistant Lyme arthritis. Arthritis Rheum. 48, 534-540 (2003).
163. Benoist C, Mathis D. Autoimmunity provoked by infection: how good is the case for T-cell epitope mimicry? Nat. Immunol. 2, 797-801 (2001). Critical evaluation of OspA autoimmunity evidence.
164. Steere AC, Levin RE, Molloy PJ et al. Treatment of Lyme arthritis. Arthritis Rheum. 37, 878-888 (1994).
165. Nocton JJ, Dressler F, Rutledge BJ, Rys PN, Persing DH, Steere AC. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis. N. Engl. J. Med. 330, 229-234 (1994).
166. Carlson D, Hernandez J, Bloom BJ, Coburn J, Aversa JM, Steere AC. Lack of Borrelia burgdorferi DNA in synovial samples from patients with antibiotic treatment-resistant Lyme arthritis. Arthritis Rheum. 42, 2705-2709 (1999).
167. Akin E, Aversa J, Steere AC. Expression of adhesion molecules in synovia of patients with treatment- resistant lyme arthritis. Infect. Immun. 69, 1774-1780 (2001).
168. Gross DM, Steere AC, Huber BT. T-helper 1 response is dominant and localized to the synovial fluid in patients with Lyme arthritis. J. Immunol. 160, 1022-1028 (1998).
169. Meyer AL, Trollmo C, Crawford F et al. Direct enumeration of Borrelia-reactive CD4 T-cells ex vivo by using MHC class II tetramers. Proc. Natl Acad. Sci. USA 97, 11433-11438 (2000).
170. Rose CD, Fawcett PT, Gibney KM. Arthritis following recombinant outer surface protein A vaccination for LD. J. Rheumatol. 28, 2555-2557 (2001).
171. Croke CL, Munson EL, Lovrich SD et al. Occurrence of severe destructive lyme arthritis in hamsters vaccinated with outer surface protein A and challenged with Borrelia burgdorferi. Infect. Immun. 68, 658-663 (2000).
172. FDA LYMErix study to test potential genetic marker for adverse events. The Pink Sheet 63, 3, February 5th 2001
173. Molloy PJ, Berardi VP, Persing DH, Sigal LH. Detection of multiple reactive protein species by immunoblotting after recombinant outer surface protein A LD vaccination. Clin. Infect. Dis. 31, 42-47 (2000).
174. Fawcett PT, Rose CD, Budd SM, Gibney KM. Effect of immunization with recombinant OspA on serologic tests for Lyme borreliosis. Clin. Diagn. Lab. Immunol. 8, 79-84 (2001).
175. Gomes-Solecki MJ, Wormser GP, Schriefer M et al. Recombinant assay for serodiagnosis of LD regardless of OspA vaccination status. J. Clin. Microbiol. 40, 193-197 (2002).
176. Marks DH, Hosbach P, Koster FT et al. Clinical studies in humans of outer surface protein A (OspA) vaccine for LD. VI International Conference on Lyme Borreliosis, Bologna, Italy, June 19-22, 1994.
177. Wormser GP, Nowakowski J, Nadelman RB et al. Efficacy of an OspA vaccine preparation for prevention of LD in New York State. Infection 26, 208-212 (1998).
178. Stover CK, Bansal GP, Hanson MS et al. Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate LD vaccine. J. Exp. Med. 178, 197-209 (1993).
179. Langermann S, Palaszynski S, Sadziene A, Stover CK, Koenig S. Systemic and mucosal immunity induced by BCG vector expressing outer- surface protein A of Borrelia burgdorferi. Nature 372, 552-555 (1994).
180. Edelman R, Palmer K, Russ KG et al. Safety and immunogenicity of recombinant Bacille Calmette-Guerin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: a candidate LD vaccine. Vaccine 17, 904-914 (1999).
181. Eder G, Barrett N, Crowe M, Gerencer M, Livey I, Low-Baselli A. A candidate OspC LD vaccine under clinical investigation. Zentralbl. Bakteriol. 289, 688-689 (1999). Brief overview of second generation LD vaccines with emphasis on OspC Phase I clinical trial.
182. Guo BP, Brown EL, Dorward DW, Rosenberg LC, Hook M. Decorin-binding adhesins from Borrelia burgdorferi. Mol. Microbiol. 30, 711-723 (1998).
183. Probert WS, Kim JH, Hook M, Johnson BJ. Mapping the ligand-binding region of Borrelia burgdorferi fibronectin- binding protein BBK32. Infect. Immun. 69, 4129-4133 (2001).
184. Parveen N, Leong JM. Identification of a candidate glycosaminoglycan-binding adhesin of the LD spirochete Borrelia burgdorferi. Mol. Microbiol. 35, 1220-1234 (2000).
185. Lam TT, Nguyen TP, Montgomery RR, Kantor FS, Fikrig E, Flavell RA. Outer surface proteins E and F of Borrelia burgdorferi, the agent of LD. Infect. Immun. 62, 290-298 (1994).
186. Fikrig E, Feng W, Barthold SW, Telford SR 3rd, Flavell RA. Arthropod- and host-specific Borrelia burgdorferi bbk32 expression and the inhibition of spirochete transmission. J. Immunol. 164, 5344-5351 (2000).
187. Labandeira-Rey M, Baker EA, Skare JT. VraA (BBI16) protein of Borrelia burgdorferi is a surface-exposed antigen with a repetitive motif that confers partial protection against experimental Lyme borreliosis. Infect. Immun. 69, 1409-1419 (2001).
188. Cassatt DR, Patel NK, Ulbrandt ND, Hanson MS. DbpA but not OspA, is expressed by Borrelia burgdorferi during spirochetemia and is a target for protective antibodies. Infect. Immun. 66, 5379-5387 (1998).
189. Hagman KE, Yang X, Wikel SK et al. Decorin-binding protein A (DbpA) of Borrelia burgdorferi is not protective when immunized mice are challenged via tick infestation and correlates with the lack of DbpA expression by B. burgdorferi in ticks. Infect. Immun. 68, 4759-4764 (2000).
190. Exner MM, Wu X, Blanco DR, Miller JN, Lovett MA. Protection elicited by native outer membrane protein Oms66 (p66) against host-adapted Borrelia burgdorferi: conformational nature of bactericidal epitopes. Infect. Immun. 68, 2647-2654 (2000).
191. Hanson MS, Patel NK, Cassatt DR, Ulbrandt ND. Evidence for vaccine synergy between Borrelia burgdorferi decorin binding protein A and outer surface protein A in the mouse model of lyme borreliosis. Infect. Immun. 68, 6457-6460 (2000).
192. Luft BJ, Johnson BJ, McGrath B, Dattwyler RJ, Dunn JJ. Chimeric protein vaccine for Lyme borreliosis. VI International Conference on Lyme Borreliosis, Bologna, Italy, June 18-22, 1994.
193. Wallich R, Siebers A, Jahraus O, Brenner C, Stehle T, Simon MM. DNA vaccines expressing a fusion product of outer surface proteins A and C from Borrelia burgdorferi induce protective antibodies suitable for prophylaxis but not for resolution of LD. Infect. Immun. 69, 2130-2136 (2001).
194. Pizza M, Scarlato V, Masignani V et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287, 1816-1820 (2000).
195. Wizemann TM, Heinrichs JH, Adamou JE et al. Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect. Immun. 69, 1593-1598 (2001).
196. Fraser CM, Casjens S, Huang WM et al. Genomic sequence of a LD spirochaete, Borrelia burgdorferi. Nature 390, 580-586 (1997).
197. Casjens S, Palmer N, van Vugt R et al. A bacterial genome in flux: the twelve linear and nine circular extrachromosomal DNAs in an infectious isolate of the LD spirochete Borrelia burgdorferi. Mol. Microbiol. 35, 490-516 (2000).
198. Das S, Barthold SW, Giles SS, Montgomery RR, Telford SR 3rd, Fikrig E. Temporal pattern of Borrelia burgdorferi p21 expression in ticks and the mammalian host. J. Clin. Invest. 99, 987-995 (1997).
199. Fikrig E, Chen M, Barthold SW et al. Borrelia burgdorferi erpT expression in the arthropod vector and murine host. Mol. Microbiol. 31, 281-290 (1999).
200. Patel NK, Alsruhe JP, Cassatt DR, Bachy CM, Hanson MS, Pizer ES. Immunohistochemical analysis of lipoprotein antigens expressed by Borrelia burgorferi during persistent infection of mice provides insights into the pathogenesis of LD. Mod. Pathol. 13, 171A (2000).
201. Ohnishi J, Piesman J, de Silva AM. Antigenic and genetic heterogeneity of Borrelia burgdorferi populations transmitted by ticks. Proc. Natl Acad. Sci. USA 98, 670-675 (2001). Thorough documentaion of Bb antigenic heterogeneity during, and just after tick transmission.
202. Fingerle V, Laux H, Munderloh UG, Schulte-Spechtel U, Wilske B. Differential expression of outer surface proteins A and C by individual Borrelia burgdorferi in different genospecies. Med. Microbiol. Immunol. (Berl) 189, 59-66 (2000).
203. Barthold SW, Fikrig E, Bockenstedt LK, Persing DH. Circumvention of outer surface protein A immunity by host-adapted Borrelia burgdorferi. Infect. Immun. 63, 2255-2261 (1995).
204. Gilmore RD Jr, Kappel KJ, Dolan MC, Burkot TR, Johnson BJ. Outer surface protein C (OspC) but not P39, is a protective immunogen against a tick-transmitted Borrelia burgdorferi challenge: evidence for a conformational protective epitope in OspC. Infect. Immun. 64, 2234-2239 (1996).
205. Feng S, Hodzic E, Barthold SW. Lyme arthritis resolution with antiserum to a 37-kilodalton Borrelia burgdorferi protein. Infect. Immun. 68, 4169-4173 (2000).
206. Barthold SW, Feng S, Bockenstedt LK, Fikrig E, Feen K. Protective and arthritis-resolving activity in sera of mice infected with Borrelia burgdorferi. Clin. Infect. Dis. 25(Suppl. 1), S9-S17 (1997).
207. Lahdenne P, Porcella SF, Hagman KE et al. Molecular characterization of a 6.6-kilodalton Borrelia burgdorferi outer membrane-associated lipoprotein (lp6.6) which appears to be downregulated during mammalian infection. Infect. Immun. 65, 412-421 (1997).
208. Liang FT, Jacobs MB, Philipp MT. C-terminal invariable domain of VlsE may not serve as target for protective immune response against Borrelia burgdorferi. Infect. Immun. 69, 1337-1343 (2001).
209. Fikrig E, Barthold SW, Sun W, Feng W, Telford SR 3rd, Flavell RA. Borrelia burgdorferi P35 and P37 proteins, expressed in vivo, elicit protective immunity. Immunity 6, 531-539 (1997).
210. Das S, Shraga D, Gannon C et al. Characterization of a 30-kDa Borrelia burgdorferi substrate-binding protein homologue. Res. Microbiol. 147, 739-751 (1996).
211. Feng S, Barthold SW, Telford SR 3rd, Fikrig E. P55, an immunogenic but nonprotective 55-kilodalton Borrelia burgdorferi protein in murine LD. Infect. Immun. 64, 363-365 (1996).
212. Wikel SK, Ramachandra RN, Bergman DK, Burkot TR, Piesman J. Infestation with pathogen-free nymphs of the tick Ixodes scapularis induces host resistance to transmission of Borrelia burgdorferi by ticks. Infect. Immun. 65, 335-338 (1997).
213. Nazario S, Das S, de Silva AM et al. Prevention of Borrelia burgdorferi transmission in guinea-pigs by tick immunity. Am. J. Trop. Med. Hyg. 58, 780-785 (1998).
214. Das S, Deponte K, Marcantonio NL et al. Granulocytic ehrlichiosis in tick-immune guinea-pigs. Infect. Immun. 66, 1803-1805 (1998).